Tubridge Flow Diverter Study For Intracranial Aneurysms
Launched by MICROPORT NEUROTECH CO., LTD. · Dec 2, 2022
Trial Information
Current as of January 21, 2025
Unknown status
Keywords
ClinConnect Summary
A cerebral aneurysm (also known as an intracranial or intracerebral aneurysm) is a weak or thin spot on a blood vessel in the brain that balloons out and fills and intermixes with parent artery blood. Incidence of intracranial aneurysms varies by country, with reports of prevalence ranging from 5.1 to 19.6 cases per 100,000 persons. The most devastating presentation of an intracranial aneurysm is subarachnoid hemorrhage (SAH). It is estimated that, on average, five percent of the population is afflicted and the incidence of aneurysm rupture (SAH) is between 6 and 9 per 1000 000 individuals ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. received Tubridge flow diverter treatment for intracranial aneurysm after the date of regulatory approval in China
- Exclusion Criteria:
- • None
Trial Officials
Jianmin Liu, Ph.D
Study Chair
Changhai Hospital
About Microport Neurotech Co., Ltd.
MicroPort NeuroTech Co., Ltd. is a leading innovator in the development of advanced neurotechnological solutions aimed at enhancing the treatment of neurological disorders. With a commitment to improving patient outcomes through cutting-edge research and development, the company specializes in the design, manufacturing, and commercialization of medical devices that address complex neurological conditions. MicroPort NeuroTech leverages its expertise in neurostimulation, neuromodulation, and neurorehabilitation to drive clinical advancements and foster collaborations within the healthcare community, ultimately striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials